Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Breakthrough Therapy designation can expedite the development and review of therapies for serious conditions(1)
In a pivotal Phase III study, oral fingolimod significantly reduced relapses by 82% in a pediatric patient population vs. interferon beta-1a ... Biopharmaceuticals, Neurology, FDA Novartis, Gilenya, Fingolimod, multiple sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Avonex | Brain | Gilenya | Multiple Sclerosis | Neurology | Pediatrics | Pharmaceuticals | Rebif | Study